Noxopharm Successfully Raises $1.5 Million via Placement
Filed with ASX · · 5 pages · English
Summary by 6ix AI
Noxopharm Ltd. has announced a successful equity raising of funds through a placement to advance its clinical program for SOF-SKN. Proceeds will support various activities including an extension study for cutaneous lupus erythematosus and other research and development efforts.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Noxopharm
- Voluntary Suspension
- Trading Halt
- 2026 AGM Letter of Access, Notice of Meeting and Proxy
- Appendix 4G and Corporate Governance Statement
- Annual Report to shareholders
Later from Noxopharm
- Reinstatement to Quotation
- Proposed issue of securities - NOX
- Quarterly Activities/Appendix 4C Cash Flow Report
- Application for quotation of securities - NOX
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm